Need and potential of antimicrobial stewardship in community hospitals

Clinical Infectious Diseases

Volumn 53, Issue SUPPL. 1, 2011, Pages

  Septimus, Edward J ^a   Owens Jr , Robert C ^b,c  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^b MAINE MEDICAL CENTER   (United States)

^c CUBIST PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; VANCOMYCIN;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL STEWARDSHIP PROGRAM; ANTIMICROBIAL THERAPY; CLINICAL PATHWAY; COMMUNITY HOSPITAL; DRUG FORMULARY; DRUG MISUSE; DRUG USE; FEEDBACK SYSTEM; GOVERNMENT; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH PROGRAM; HEARING LOSS; HOSPITAL PERSONNEL; HUMAN; INFECTION; KIDNEY DISEASE; LENGTH OF STAY; MEDICAL AUDIT; MEDICAL EDUCATION; MEDICAL SPECIALIST; MEDICARE; MORBIDITY; MORTALITY; OPTIMAL DRUG DOSE; PHARMACIST ATTITUDE; PHYSICIAN ATTITUDE; POSTOPERATIVE INFECTION; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SURGICAL PATIENT; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; DRUG UTILIZATION; DRUG UTILIZATION REVIEW; HEALTH RESOURCES; HOSPITALS, COMMUNITY; HUMANS; INFECTIOUS DISEASE MEDICINE; PHARMACISTS; PRACTICE GUIDELINES AS TOPIC; PUBLIC HEALTH;

EID: 79960999358     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir363     Document Type: Review

References (32)

1. Talbot GH, Bradley J, Edwards JE Jr., Gilbert D, Scheld M, Bartlett JG. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 2006; 42:657-68. (Pubitemid 43271379)
2. Wenzel RP, Bearman G, Edmond MB. Screening for MRSA: a flawed hospital infection control intervention. Infect Control Hosp Epidemiol 2008; 29:1012-8.
3. Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009; 302:2323-9.
4. European Centre for Disease Prevention and Control, European Medicines Agency. ECDC/EMEA Joint Technical Report: the bacterial challenge: time to react. Available at: http://www.ecdc.europa.eu/en/publications/Publications/ Forms/ECDC-DispForm.aspx?ID5444. Accessed 27 September.
5. Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis 2008; 197:1079-81. (Pubitemid 351590040)
6. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:1-12.
7. Miller LG, Perdreau-Remington F, Rieg G, et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med 2005; 352:1445-53. (Pubitemid 40471452)
8. Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005; 352:1436-44.
9. Kaplan SL, Hulten KG, Gonzalez BE, et al. Three-year surveillance of community-acquired Staphylococcus aureus infections in children. Clin Infect Dis 2005; 40:1785-91. (Pubitemid 40799948)
10. King MD, Humphrey BJ, Wang YF, Kourbatova EV, Ray SM, Blumberg HM. Emergence of community-acquired methicillinresistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann Intern Med 2006; 144:309-17. (Pubitemid 46768185)
11. Moran GJ, Amii RN, Abrahamian FM, Talan DA. Methicillin-resistant Staphylococcus aureus in community-acquired skin infections. Emerg Infect Dis 2005; 11:928-30. (Pubitemid 40720855)
12. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006; 355:666-74.
13. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin- resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:285-92.
14. Wilcox MH, Mooney L, Bendall R, Settle CD, Fawley WN. A casecontrol study of community-associated Clostridium difficile infection. J Antimicrob Chemother 2008; 62:388-96. (Pubitemid 351984787)
15. Rabatsky-Ehe T, Purviance K, Mlynarski D, et al. Surveillance for community-associated Clostridium difficile-Connecticut, 2006. MMWR Morb Mortal Wkly Rep 2008; 57:340-3.
16. Delaney JA, Dial S, Barkun A, Suissa S. Antimicrobial drugs and community-acquired Clostridium difficile-associated disease, UK. Emerg Infect Dis 2007; 13:761-3. (Pubitemid 46698741)
17. Dellit TH, Owens RC, McGowan JE Jr., et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007; 44:159-77. (Pubitemid 46084814)
18. Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 2003; 289:885-8. (Pubitemid 37430348)
19. Hecker MT, Aron DC, Patel NP, Lehmann MK, Donskey CJ. Unnecessary use of antimicrobials in hospitalized patients: current patterns of misuse with an emphasis on the antianaerobic spectrum of activity. Arch Intern Med 2003; 163:972-8. (Pubitemid 36519743)
20. Rapp RP, Kaye KS, Canon SB, Hermsen ED, DePestel DD. A hospital pharmacist's guide to antimicrobial stewardship programs. Available at: http://onlinece.ashpadvantage.com/stewardship/stewardship-white-paper.pdf. Accessed 6 September 2010.
21. LaRosa LA, Fishman NO, Lautenbach E, Koppel RJ, Morales KH, Linkin DR. Evaluation of antimicrobial therapy orders circumventing an antimicrobial stewardship program: investigating the strategy of "stealth dosing". Infect Control Hosp Epidemiol 2007; 28:551-6. (Pubitemid 46814544)
22. Linkin DR, Paris S, Fishman NO, Metlay JP, Lautenbach E. Inaccurate communications in telephone calls to an antimicrobial stewardship program. Infect Control Hosp Epidemiol 2006; 27:688-94. (Pubitemid 44271949)
23. Larson EL, Quiros D, Giblin T, Lin S. Relationship of antimicrobial control policies and hospital and infection control characteristics to antimicrobial resistance rates. Am J Crit Care 2007; 16:110-20.
24. Shlaes DM, Gerding DN, John JF Jr., et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Infect Control Hosp Epidemiol 1997; 18:275-91. (Pubitemid 127470480)
25. Calbo E, Garau J. Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of community-acquired respiratory tract infections. Respiration 2005; 72:561-71. (Pubitemid 41798131)
26. Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003; 37:752-60. (Pubitemid 37153652)
27. Noreddin AM, Hoban DJ, Zhanel GG. Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae. Int J Antimicrob Agents 2005; 26:120-5. (Pubitemid 41021963)
28. Ford W. New strategies in antimicrobial stewardship: managing patient care. Available at: http://idse.net/ViewArticle.aspx?d5 Bacterial1Infections1/ 1MRSA&d-id5211&i5September12010& i-id5665&a-id515903. Accessed 10 November 2010.
29. ASHP statement on the pharmacist's role in antimicrobial stewardship and infection prevention and control. Am JHealth Syst Pharm 2010; 67:575-7.
30. Gross R, Morgan AS, Kinky DE, Weiner M, Gibson GA, Fishman NO. Impact of a hospital-based antimicrobial management programon clinical and economic outcomes. Clin Infect Dis 2001; 33:289-95. (Pubitemid 32664829)
31. Bond CA, Raehl CL. Clinical and economic outcomes of pharmacistmanaged antimicrobial prophylaxis in surgical patients. Am J Health Syst Pharm 2007; 64:1935-42. (Pubitemid 47462909)
32. Bond CA, Raehl CL. Clinical and economic outcomes of pharmacistmanaged aminoglycoside or vancomycin therapy. Am J Health Syst Pharm 2005; 62:1596-605. (Pubitemid 41060472)